Besides the studies of NAAG in brain cancers like glioma (47), it has been reported that NAAG can serve as a reservoir to provide glutamate to tumor cells in cancers expressing GCPII, such as ovarian cancer, where NAAG is more abundant in more malignant tumors and its concentration in plasma is correlated with tumor size (48). This evidence concerns the gene FOLH1 and central nervous system cancer.